Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15510073 | 0.83 | BACE1 (0.46) | MEN1KMT2AROCK2HDAC6NAMPT | |
| SCHEMBL3273087 | 0.82 | PDK2 (0.45) | KMT2ANAMPTPOLBNPC1 | |
| SCHEMBL3273293 | 0.80 | RAB9A (0.48) | MEN1KMT2AHDAC6POLBNPC1 | |
| SCHEMBL3272894 | 0.69 | BACE1 (0.41) | NAMPTNPC1CNR2 | |
| SCHEMBL15509542 | 0.69 | CNR2 (0.51) | KMT2ANPC1SMN1; SMN2CNR2 | |
| SCHEMBL3457717 | 0.68 | HPGD (0.67) | MEN1KMT2AROCK2HDAC6MLYCD | |
| SCHEMBL10722330 | 0.68 | MEN1 (0.81) | MEN1KMT2AHDAC6POLBMLYCD | |
| SCHEMBL10722498 | 0.67 | HDAC6 (0.77) | MEN1KMT2AHDAC6NAMPTPOLB | |
| SCHEMBL25123079 | 0.66 | SMN1; SMN2 (0.76) | MEN1KMT2AHDAC6NAMPTPOLB | |
| SCHEMBL4522241 | 0.66 | SMN1; SMN2 (0.76) | MEN1KMT2AHDAC6NAMPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | MEN1 4037/4885KMT2A 3308/4885ROCK2 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.